Sensus Healthcare
Sensus Healthcare's revenue fell 34.3% to $28 million in fiscal 2025. Its operating margin was −37.5%, down from 19.4% a year earlier. Free cash flow was $0 million. It paid out $0 million in dividends and buybacks, 90% of free cash flow. The diluted share count fell 0.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2021 to 2024, earnings per share grew 17.9% a year and net income 17.2% a year, as buybacks cut the share count by 1%. Sensus Healthcare then lost money in fiscal 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 14 | 26 | 23 | 22 | 22 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | 2,060.0x | 39.0x | −0.4x | 8.7x | — |
| Current ratio | 5.2x | 6.9x | 11.8x | 9.6x | 9.7x |
| Quick ratio | 4.9x | 6.5x | 8.9x | 7.9x | 6.6x |
Cash flow
Projections
Project Sensus Healthcare's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $791,628 of Sensus Healthcare shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Megan CornishDirector | Bought | 2,200 | $2.28 | $5,016 | Form 4 |
| Nov 17, 2026 | Eric SachettaDirector | Bought | 81,575 | $2.24 | $182,973 | Form 4 |
| Aug 31, 2026 | Eric SachettaDirector | Bought | 27,304 | $3.54 | $96,656 | Form 4 |
| Aug 28, 2026 | Eric SachettaDirector | Bought | 37,537 | $3.44 | $129,127 | Form 4 |
| Aug 27, 2026 | Eric SachettaDirector | Bought | 10,925 | $3.18 | $34,742 | Form 4 |
| Aug 26, 2026 | Eric SachettaDirector | Bought | 9,708 | $3.29 | $31,939 | Form 4 |
| Aug 24, 2026 | Eric SachettaDirector | Bought | 34,697 | $3.25 | $112,765 | Form 4 |
| Aug 21, 2026 | Eric SachettaDirector | Bought | 7,000 | $3.25 | $22,750 | Form 4 |
| Aug 20, 2026 | Eric SachettaDirector | Bought | 24,000 | $3.13 | $75,120 | Form 4 |
| Aug 20, 2026 | Joseph C SardanoChief Executive Officer, Director | Bought | 20,000 | $3.02 | $60,400 | Form 4 |
| May 12, 2026 | Eric SachettaDirector | Bought | 1,500 | $3.34 | $5,010 | Form 4 |
| Feb 24, 2026 | Eric SachettaDirector | Bought | 2,000 | $3.81 | $7,620 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −54.9% | 68.7% | −33.1% |
| Altman Z'' | 16.43 | 16.19 | 14.36 |
| Accruals ratio | 4.8% | 12.9% | −14.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Fail | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Pass | Fail | Pass |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | — | — | — |
Compare
Put Sensus Healthcare side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Sensus Healthcare | FY25 | −34.3% | −37.5% | 1.2% | — | — | — | |
| Precision Optics Corporation | FY26 | 65.2% | −11.1% | −6.3% | −22.8% | — | 5 | Compare |
| electroCore | FY25 | 27.2% | −41.1% | −25.8% | — | — | — | Compare |
| Stereotaxis | FY25 | 20.3% | −68.3% | −42.5% | — | — | — | Compare |
| Orchestra BioMed | FY25 | 1,169.2% | −154.7% | −147.7% | — | — | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 15 | 21 | 26 | 27 | 10 | 27 | 44 | 24 | 42 | 28 |
| Revenue growth | 44.2% | 39.0% | 28.4% | 3.2% | −64.9% | 182.4% | 64.7% | −45.2% | 71.3% | −34.3% |
| Gross profit | 10 | 14 | 17 | 18 | 5 | 17 | 30 | 14 | 24 | 12 |
| Research and development | 2 | 6 | 6 | 6 | 4 | 3 | 4 | 4 | 4 | 8 |
| Operating income | −0 | −4 | −2 | −2 | −8 | 4 | 15 | −0 | 8 | −10 |
| Net income | −0 | −4 | −2 | −2 | −7 | 4 | 24 | 0 | 7 | −8 |
| Diluted EPS (US$) | −0.03 | −0.28 | −0.14 | −0.10 | −0.42 | 0.25 | 1.46 | 0.03 | 0.41 | −0.47 |
| Diluted shares (millions) | 12 | 13 | 14 | 16 | 16 | 16 | 17 | 16 | 16 | 16 |
| Cash flow | ||||||||||
| Cash from operations | −1 | −3 | −9 | −2 | −0 | −0 | −1 | −2 | −1 | 0 |
| Capital expenditure | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −1 | −3 | −9 | −3 | −1 | −0 | −2 | −2 | −1 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 5 | 10 | 12 | 8 | 15 | 14 | 26 | 23 | 22 | 22 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 19 | 19 | 33 | 37 | 28 | 32 | 57 | 54 | 62 | 53 |
| Total liabilities | 4 | 7 | 7 | 9 | 6 | 6 | 9 | 5 | 6 | 5 |
| Shareholders' equity | 15 | 12 | 26 | 28 | 22 | 26 | 48 | 49 | 56 | 48 |
| Margins and ratios | ||||||||||
| Gross margin | 66.5% | 67.0% | 64.0% | 64.4% | 54.8% | 62.8% | 66.5% | 57.6% | 58.4% | 43.2% |
| Operating margin | −2.5% | −18.1% | −7.6% | −7.2% | −86.0% | 15.2% | 33.3% | −1.6% | 19.4% | −37.5% |
| Net margin | −2.3% | −18.0% | −7.7% | −6.2% | −71.4% | 15.2% | 54.4% | 2.0% | 15.9% | −28.1% |
| Free cash flow margin | −7.7% | −16.2% | −35.6% | −9.2% | −8.3% | −1.5% | −3.5% | −9.7% | −2.6% | 1.2% |
| Rule of 40 (growth + FCF margin) | 36.5% | 22.8% | −7.3% | −6.0% | −73.2% | 180.8% | 61.1% | −54.9% | 68.7% | −33.1% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −3.3% | −27.5% | −10.6% | −6.2% | −27.6% | 17.3% | 65.5% | 1.0% | 12.7% | −14.8% |
| Return on assets | −2.4% | −19.6% | −7.8% | −4.8% | −21.1% | 13.7% | 54.5% | 0.9% | 11.5% | −13.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |